Overview

SHIFT: Studying HIV Immunology After Fecal Transplant

Status:
Withdrawn
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
SHIFT is a randomized, longitudinal, prospective, blinded, three-arm study to determine the safety and tolerability of Fecal Microbiota Transplant (FMT) in HIV-infected participants on stable antiretroviral therapy (ART).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Anti-Bacterial Agents
Antibiotics, Antitubercular